Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study

Pharmacogenomics

Volumn 13, Issue 11, 2012, Pages 1227-1237

  Liu, Qian ^a   Jamba, Maidar ^a   Patrick Iii, Calvin ^a   Padmanabhan, Saranya ^a   Brennan, Mark D ^a  

^a SureGene LLC   (United States)

Author keywords

neuropsychiatric genes; olanzapine; perphenazine; quetiapine; risperidone; ziprasidone

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CAUCASIAN; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG RESPONSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MENTAL DISEASE; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; UNITED STATES;

EID: 84865478319     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.105     Document Type: Article

References (59)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). (Pubitemid 41345943)
2. Stroup TS, McEvoy JP, Swartz MS et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 29(1), 15-31 (2003). (Pubitemid 36871054)
3. Kane JM. Pharmacologic treatment of schizophrenia. Biol. Psychiatry 46(10), 1396-1408 (1999).
4. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF. A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr. Res. 107(1), 13-21 (2009).
5. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry 161(5), 780-796 (2004). (Pubitemid 38625331)
6. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur. J. Hum. Genet. 14(6), 669-680 (2006). (Pubitemid 43797264)
7. Stefansson H, Ophoff RA, Steinberg S et al. Common variants conferring risk of schizophrenia. Nature 460(7256), 744-747 (2009).
8. Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40(7), 827-834 (2008). (Pubitemid 351913655)
9. Cook EH Jr, Scherer SW. Copy-number variations associated with neuropsychiatric conditions. Nature 455(7215), 919-923 (2008).
10. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 455(7210), 232-236 (2008).
11. Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I et al. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am. J. Hum. Genet. 83(4), 504-510 (2008).
12. McClay JL, Adkins DE, Aberg K et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 16(1), 76-85 (2011).
13. Need AC, Keefe RS, Ge D et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 17(7), 946-957 (2009).
14. Manolio TA, Rodriguez LL, Brooks L et al. New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat. Genet. 39(9), 1045-1051 (2007). (Pubitemid 47340660)
15. Sullivan PF, Lin D, Tzeng JY et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol. Psychiatry 13(6), 570-584 (2008). (Pubitemid 351704941)
16. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007). (Pubitemid 47330214)
17. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am. J. Psychiatry 166(6), 639-641 (2009).
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
19. Barrett JC. Haploview: visualization and analysis of SNP genotype data. Cold Spring Harb. Protoc. 2009(10), pdb.ip71 (2009).
20. Bao L, Zhou M, Wu L et al. PolymiRTS Database: linking polymorphisms in microRNA target sites with complex traits. Nucleic Acids Res. 35(Database issue), D51-D54 (2007). (Pubitemid 46056169)
21. Ziebarth JD, Bhattacharya A, Chen A, Cui Y. PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res. 40(Database issue), D216-D221 (2012).
22. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet. 84(2), 210-223 (2009).
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57(1), 289-300 (1995).
24. Havik B, Le HS, Rietschel M et al. The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. Biol. Psychiatry 70(1), 35-42 (2011).
25. Need AC, Ge D, Weale ME et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 5(2), e1000373 (2009).
26. Ripke S, Sanders AR, Kendler KS et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 43(10), 969-976 (2011).
27. Suarez BK, Duan J, Sanders ARet al. Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. Am. J. Hum. Genet. 78(2), 315-333 (2006). (Pubitemid 43157570)
28. Curtis D, Vine AE, McQuillin A et al. Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes. Psychiatr. Genet. 21(1), 1-4 (2011).
29. Holmans PA, Riley B, Pulver AE et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol. Psychiatry 14(8), 786-795 (2009).
30. Shi J, Levinson DF, Duan J et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460(7256), 753-757 (2009).
31. Macintyre G, Alford T, Xiong L, Rouleau GA, Tibbo PG, Cox DW. Association of NPAS3 exonic variation with schizophrenia. Schizophr. Res. 120(1-3), 143-149 (2010).
32. Pickard BS, Christoforou A, Thomson PA et al. Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol. Psychiatry 14(9), 874-884 (2009).
33. Huang J, Perlis RH, Lee PH et al. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am. J. Psychiatry 167(10), 1254-1263 (2010).
34. Wang KS, Liu XF, Aragam N. A genome-wide meta-analysis identifies novel loci associated with schizophrenia and bipolar disorder. Schizophr. Res. 124(1-3), 192-199 (2010).
35. Ferreira MA, O'Donovan MC, Meng YA et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40(9), 1056-1058 (2008).
36. Baum AE, Akula N, Cabanero M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry 13(2), 197-207 (2008).
37. Lasky-Su J, Neale BM, Franke B et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(8), 1345-1354 (2008).
38. Lesch KP, Timmesfeld N, Renner TJ et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J. Neural Transm. 115(11), 1573-1585 (2008).
39. Ma D, Salyakina D, Jaworski JM et al. A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. Ann. Hum. Genet. 73(Pt 3), 263-273 (2009).
40. Ozgen HM, van DE, Bolton PF et al. Copy number changes of the microcephalin 1 gene (MCPH1) in patients with autism spectrum disorders. Clin. Genet. 76(4), 348-356 (2009).
41. Cannon DS, Miller JS, Robison RJ et al. Genome-wide linkage analyses of two repetitive behavior phenotypes in Utah pedigrees with autism spectrum disorders. Mol. Autism 1(1), 3 (2010).
42. Roohi J, Montagna C, Tegay DH et al. Disruption of contactin 4 in three subjects with autism spectrum disorder. J. Med. Genet. 46(3), 176-182 (2009).
43. Glessner JT, Wang K, Cai G et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459(7246), 569-573 (2009).
44. Edwards TL, Scott WK, Almonte C et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74(2), 97-109 (2010).
45. Burns LC, Minster RL, Demirci FY et al. Replication study of genome-wide associated SNPs with late-onset Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B(4), 507-512 (2011).
46. Cirulli ET, Kasperaviciute D, Attix DK et al. Common genetic variation and performance on standardized cognitive tests. Eur. J. Hum. Genet. 18(7), 815-820 (2010).
47. Seshadri S, DeStefano AL, Au Ret et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC. Med. Genet. 8(Suppl. 1), S15 (2007).
48. Terracciano A, Sanna S, Uda M et al. Genome-wide association scan for five major dimensions of personality. Mol. Psychiatry 15(6), 647-656 (2010).
49. Terracciano A, Tanaka T, Sutin ARet al. Genome-wide association scan of trait depression. Biol. Psychiatry 68(9), 811-817 (2010).
50. Lavedan C, Licamele L, Volpi S et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol. Psychiatry 14(8), 804-819 (2009).
51. Hulea L, Nepveu A. CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases. Gene 497(1), 18-26 (2012).
52. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain Res. 172, 177-197 (2008).
53. Ramsey TL, Meltzer HY, Brock GN et al. Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12(4), 471-480 (2011).
54. Rimol LM, Agartz I, Djurovic S et al. Sex-dependent association of common variants of microcephaly genes with brain structure. Proc. Natl Acad. Sci. USA 107(1), 384-388 (2010).
55. Han MR, Schellenberg GD, Wang LS. Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study. BMC. Neurol. 10, 90 (2010).
56. Vemuri P, Weigand SD, Przybelski SA et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain 134(Pt 5), 1479-1492 (2011).
57. Newton PM, Messing RO. The substrates and binding partners of protein kinase Cepsilon. Biochem. J. 427(2), 189-196 (2010).
58. Wang B, Harrison W, Overbeek PA, Zheng H. Transposon mutagenesis with coat color genotyping identifies an essential role for Skor2 in sonic hedgehog signaling and cerebellum development. Development 138(20), 4487-4497 (2011).
59. Xing C, Torres-Caban M, Wang T, Lu Q, Xing G, Elston RC. Linkage studies of catechol-O-methyltransferase (COMT) and dopamine-beta-hydroxylase (DBH) cDNA expression levels. BMC. Proc. 1(Suppl. 1), S95 (2007).